Table 2. Enrollment stopping roles

|  |
| --- |
| Criteria |
| * Serious adverse event (SAE) assessed through 7 days post-infusion that was unexpected and was related to investigational product
 |
| * Death that was related to investigational product
 |
| * Any subject experiencing any Grade 3 or 4 infusion-related allergic reactions occurring in the first 24 hours post-infusion
 |
| * Any subject experiencing neurological worsening of ≥4 points on the NIHSS assessed through 7 days post-infusion that was related to investigational product
 |

Enrollment will be stopped until the DSMB can review the event and determine if it is safe to continue enrollment